Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
BRAVE-AA1 (NCT03570749) and BRAVE-AA2 (NCT03899259) were registered on 18 June, 2018, and 1 April, 2019, respectively.
Authors
- Ulrike Blume‐Peytavi (ORCID: https://orcid.org/0000-0003-3528-3752)
- Jill Kolodsick
- Bianca Maria Piraccini (ORCID: https://orcid.org/0000-0001-6537-9689)
- Ayush Srivastava
- Rodney Sinclair (ORCID: https://orcid.org/0000-0001-6751-1428)
- Yutaka Shimomura (ORCID: https://orcid.org/0000-0001-9727-8073)
- Angelina Sontag (ORCID: https://orcid.org/0000-0003-4012-4537)
- Brett King (ORCID: https://orcid.org/0000-0002-4576-4616)
- Yves Dutronc (ORCID: https://orcid.org/0000-0002-1284-1152)
- Arash Mostaghimi (ORCID: https://orcid.org/0000-0002-6084-5617)
- Xiaoyu Lu (ORCID: https://orcid.org/0009-0008-2588-9826)
- Karen Denning
Institutions
- Fairfield University (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- The University of Melbourne (AU)
- Eli Lilly (United States) (US)
- Yamaguchi University (JP)
- Yale University (US)
- Charité - Universitätsmedizin Berlin (DE)
- University of Bologna (IT)
Publication Details
- Journal
- American Journal of Clinical Dermatology
- Published
- 2025-04-11
- DOI
- https://doi.org/10.1007/s40257-025-00932-0
- Citations
- 5
- Primary Topic
- Hair Growth and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 9.18
Funders
- American Academy of Dermatology
- Eli Lilly and Company